Trump's For Pick FDA Head Talks About Drug Prices And Approvals
Dr. Joseph Gulfo confirmed that he has spoken with the administration of US President Donald Trump regarding him being named FDA Commissioner. Gulfo has outlined his views on how the FDA should approve drugs and work on lowering the prices. Gulfo stated that the FDA forces companies to prove that their products measurably improve patient outcomes and delaying approvals thus increasing the drug prices.
Gulfo gave the example of cholesterol lowering drugs Praluent and Repatha. He stated that although the drugs lowered LDL cholesterol in clinical studies, the indications were limited by the agency pending the outcomes of long-term cardiovascular trials of the drugs. According to Gulfo, he recommends a four-tier system of approving drugs. This ranges from the lowest level of evidence of affecting a biomarker to the highest level at which there are confirmed life-prolonging effects.
Last year the FDA approved Sarepta Therapeutics’ Exondys 51, a Duchenne muscular dystrophy drug. This gave patients greater leeway in judging the risk-benefit ratio. The critics of the relaxed rules contend that there is no evidence that the drug companies will lower drug prices once restrictions on drug approvals will be eased up by the agency according to a report by FirstWord Pharma.
Gulfo has held senior roles at a number of biopharma companies in the past. Gulfo is a medical doctor and an M.B.A. and is currently the executive director of Lewis Center for Healthcare Innovation and Technology. Although Gulfo has not commented publicly on his candidacy, he made it clear recently that he would be interested serving the Trump Administration as the FDA chief. He said that he would be honored to serve President Trump and bring real reform to the FDA.
Dr. Joseph Gulfo has been an outspoken critic of the FDA and has penned a manifesto for its reform. Gulfo joints a list of possible candidates to head the agency. The list also includes tech capitalist Jim O’Neill, Balaji Srinivasan, a specialist in computational biology and Scott Gottlieb, a former FDA staffer and a partner at venture capital fund New Enterprise Associates as reported in an article by FierceBiotech.
VA’s Agent Orange Policy Leaves Navy Veterans High And Dry
A new bill is introduced to correct the VA’s Agent Orange policy and to restore the presumption that Blue Water Veterans could have been exposed to Agent Orange and other toxic herbicides during their service in Vietnam.
NASA’s New Horizons heads for new adventures after Pluto
With NASA’s New Horizons mission to Pluto over, the spacecraft is now headed to other parts of the solar system beyond the dwarf planet to studies objects in Kuiper Belt.
MORE IN ITECHPOST
All You Need To Know About Massage Gun
There is always a probability of feeling pain in your body after exercise. The pain is even likely to affect your routine activities. So, it is essential to take care of it before the reverse occurs. Before now, the use of foam roller has been in the vanguard of suppressing muscle pains.
Facebook is Launching a Dating App in the U.S.
Facebook announced early in September that it will be rolling out its latest service in the U.S.: a dating platform. Known as Facebook Dating, the platform can be accessed via the Facebook app.
New Retroreflective Material Could be Used in Nighttime Color-Changing Road Signs
BUFFALO, N.Y. -- A thin film that reflects light in intriguing ways could be used to make road signs that shine brightly and change color at night, according to a study that will be published on Aug. 9 in Science Advances.
Top 5 Video Games to Play for a Truly Unique First Date
Video games have a way of taking us outside of ourselves and live in a fantasy world. It's even better when you're playing a game with someone special!